查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1589599

透过血脑障壁的药物输送市场：按药物输送技术、按应用分类 - 全球预测 2025-2030

Drug Delivery Across Blood Brain Barrier Market by Drug Delivery Technology (Bispecific Antibody RMT Approach, Passive Diffusion, Permeability Increase of BBB), Application (Alzheimer's Disease, Brain Cancer, Epilepsy) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年血脑障壁给药市值为6.6715亿美元，预计2024年将达到7.2697亿美元，复合年增长率为9.06%，预计到2030年将达到12%，预计将达到24.38美元十亿。

跨越血脑障壁（BBB）的药物输送的范围和定义包括跨越这种选择性渗透性屏障输送治疗药物以治疗阿兹海默症、帕金森氏症和脑肿瘤等脑部相关疾病的技术。的方法这种机制至关重要，因为血脑障壁发挥保护大脑免受外来物质侵害的作用，同时防止许多潜在的治疗药物进入中枢神经系统。由于传统药物在治疗神经系统疾病方面效果有限，因此需要这种传递系统，并推动了标靶治疗领域的发展。其在製药和生物技术行业的应用不断扩大，其中奈米颗粒、脂质体和共轭分子等创新递送方法的开发发挥重要作用。最终使用者包括需要准确有效治疗方法的医院、研究机构和专科诊所。

主要市场统计
基准年[2023] 66715万美元
预测年份 [2024] 7.2697 亿美元
预测年份 [2030] 1,224.38 百万美元
复合年增长率（%） 9.06%

市场驱动因素包括神经系统疾病盛行率的增加、奈米技术的进步以及研发投资的快速增加。研究机构和製药公司之间的合作旨在创新有效的药物输送解决方案并将其商业化，这是一个潜在的商机。但市场面临监管要求复杂、开发成本高、技术障碍等挑战。此外，病人安全问题和道德考量构成了主要障碍。该领域的创新可集中于提高治疗的生物有效性和特异性、增强非侵入性递送方法以及探索跨血脑屏障的新型分子转运机制。

该市场竞争激烈，但探索的时机已经成熟，重点是战略伙伴关係关係、专利申请和跨学科研究合作以实现突破。最终，持续努力建立强大的临床试验和监管框架对于利用市场机会至关重要。追求智慧药物输送系统的进步并利用人工智慧主导的平台来实现个人化医疗有可能彻底改变神经系统疾病的治疗模式，这是一个备受期待的未来发展领域。

市场动态：快速发展的血脑障壁介导的药物输送市场的关键市场洞察

供需的动态交互作用正在改变跨血脑障壁的药物输送市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 阿兹海默症神经系统疾病的增加
    • 失智症盛行率上升主要影响老年人口
    • 长期照护患者的医疗支出增加
  • 市场限制因素
    • 血脑障壁（BBB）有效限制治疗药物渗入大脑
  • 市场机会
    • 越来越多地使用奈米技术来治疗各种医疗状况
    • 医疗旅游业和长期照护设施的成长
    • 加大医药研发投入
  • 市场挑战
    • 与治疗药物相关的严重副作用

波特五力：开拓血脑障壁药物输送市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解对血脑障壁药物输送市场的外部影响

外部宏观环境因素在塑造血脑障壁介导的药物传输市场的绩效动态方面发挥关键作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解血脑障壁给药市场的竞争状况

对血脑障壁药物输送市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来发现自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵血脑障壁介导的药物传输市场供应商的绩效评估

FPNV 定位矩阵是评估血脑障壁药物输送市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了血脑障壁介导的药物输送市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对血脑障壁药物输送市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 阿兹海默症神经系统疾病的发生率增加
      • 失智症盛行率上升，主要影响老年人口
      • 长期照护患者的医疗费用增加
    • 抑制因素
      • 血脑障壁（BBB）有效限制治疗药物渗入大脑
    • 机会
      • 越来越多地使用奈米技术来治疗各种医疗状况
      • 不断发展的医疗旅游业和长期照护设施
      • 加大医药研发投入
    • 任务
      • 与治疗药物相关的严重副作用
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章血脑障壁给药市场：透过给药技术

  • 双特异性抗体 RMT 方法
  • 被动扩散
  • 血脑屏障渗透性增加
  • 特洛伊木马的方法

第七章血脑障壁市场：依应用分类

  • 阿兹海默症
  • 脑肿瘤
  • 癫痫
  • 韩特氏症
  • 多发性硬化症
  • 帕金森氏症

第八章美洲血脑障壁药物输送市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太血脑障壁给药市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章 欧洲、中东和非洲的血脑障壁给药市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争场景分析
  • 战略分析和建议

公司名单

  • 3M Company
  • AbbVie Inc.
  • Angiochem Inc.
  • Bioasis Technologies Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Carthera SA
  • CNS Pharmaceuticals, Inc.
  • Cordance Medical Inc.
  • F. Hoffmann-La Roche Ltd.
  • ICON PLC
  • JCR Pharmaceuticals Co., Ltd.
  • Nanoform Finland Oyj
  • Ossianix, Inc.
  • Pfizer Inc.
Product Code: MRR-221461477305

The Drug Delivery Across Blood Brain Barrier Market was valued at USD 667.15 million in 2023, expected to reach USD 726.97 million in 2024, and is projected to grow at a CAGR of 9.06%, to USD 1,224.38 million by 2030.

The scope and definition of drug delivery across the blood-brain barrier (BBB) encompass techniques and technologies focused on delivering therapeutic agents across this selective permeability barrier to target brain-related conditions such as Alzheimer's, Parkinson's, and brain tumors. This mechanism is crucial due to the BBB's role in protecting the brain from foreign substances while concurrently impeding many potential therapeutic agents from entering the CNS. The necessity for such delivery systems arises from the limited efficacy of conventional drugs in treating neurological disorders, thus advancing the field of targeted therapy. Applications extend across pharmaceuticals and biotechnology industries where developing innovative delivery methods, such as nanoparticles, liposomes, and conjugated molecules, play critical roles. End-user segments include hospitals, research institutes, and specialty clinics that require precise and effective treatment options.

KEY MARKET STATISTICS
Base Year [2023] USD 667.15 million
Estimated Year [2024] USD 726.97 million
Forecast Year [2030] USD 1,224.38 million
CAGR (%) 9.06%

Market insights reveal several growth drivers, including increasing prevalence of neurological disorders, advancements in nanotechnology, and a surge in R&D investments. Collaborations between research organizations and pharmaceutical companies present potential opportunities, as industries seek to innovate and commercialize effective drug delivery solutions. However, the market faces challenges such as complex regulatory requirements, high developmental costs, and technological barriers. Additionally, patient safety concerns and ethical considerations also pose significant hurdles. Innovating within this space could focus on improving the bioavailability and specificity of therapeutic agents, enhancing non-invasive delivery methods, and exploring novel molecular transport mechanisms across the BBB.

The nature of the market is competitive yet ripe for exploration, emphasizing strategic partnerships, patent acquisitions, and multidisciplinary research collaborations to achieve breakthroughs. Ultimately, pitching efforts toward building a robust framework for clinical trials and regulatory pathways is vital for capitalizing on market opportunities. Pursuing advancements in smart drug delivery systems and leveraging AI-driven platforms for personalized medicine are highly promising areas for future development, potentially revolutionizing treatment paradigms for neurological conditions.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Drug Delivery Across Blood Brain Barrier Market

The Drug Delivery Across Blood Brain Barrier Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing incidences of neurological disorders, such as Alzheimer's disease
    • Rising prevalence of dementia, majorly affecting the elderly population
    • Rising healthcare expenditure for long term care patients
  • Market Restraints
    • Blood-brain barrier (BBB) efficiently restricts penetration of therapeutic agents to the brain
  • Market Opportunities
    • Increasing the use of nanotechnology in treating various medical conditions
    • Growing medical tourism industry and long-term care facilities
    • Growing investment in pharmaceutical research & development
  • Market Challenges
    • Serious side effects associated with therapeutic drugs

Porter's Five Forces: A Strategic Tool for Navigating the Drug Delivery Across Blood Brain Barrier Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Drug Delivery Across Blood Brain Barrier Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Drug Delivery Across Blood Brain Barrier Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Drug Delivery Across Blood Brain Barrier Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Drug Delivery Across Blood Brain Barrier Market

A detailed market share analysis in the Drug Delivery Across Blood Brain Barrier Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Drug Delivery Across Blood Brain Barrier Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Drug Delivery Across Blood Brain Barrier Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Drug Delivery Across Blood Brain Barrier Market

A strategic analysis of the Drug Delivery Across Blood Brain Barrier Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Drug Delivery Across Blood Brain Barrier Market, highlighting leading vendors and their innovative profiles. These include 3M Company, AbbVie Inc., Angiochem Inc., Bioasis Technologies Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Carthera S.A., CNS Pharmaceuticals, Inc., Cordance Medical Inc., F. Hoffmann-La Roche Ltd., ICON PLC, JCR Pharmaceuticals Co., Ltd., Nanoform Finland Oyj, Ossianix, Inc., and Pfizer Inc..

Market Segmentation & Coverage

This research report categorizes the Drug Delivery Across Blood Brain Barrier Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Delivery Technology, market is studied across Bispecific Antibody RMT Approach, Passive Diffusion, Permeability Increase of BBB, and Trojan Horse Approach.
  • Based on Application, market is studied across Alzheimer's Disease, Brain Cancer, Epilepsy, Hunter's Syndrome, Multiple Sclerosis, and Parkinson's Disease.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing incidences of neurological disorders, such as Alzheimer's disease
      • 5.1.1.2. Rising prevalence of dementia, majorly affecting the elderly population
      • 5.1.1.3. Rising healthcare expenditure for long term care patients
    • 5.1.2. Restraints
      • 5.1.2.1. Blood-brain barrier (BBB) efficiently restricts penetration of therapeutic agents to the brain
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing the use of nanotechnology in treating various medical conditions
      • 5.1.3.2. Growing medical tourism industry and long-term care facilities
      • 5.1.3.3. Growing investment in pharmaceutical research & development
    • 5.1.4. Challenges
      • 5.1.4.1. Serious side effects associated with therapeutic drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Drug Delivery Across Blood Brain Barrier Market, by Drug Delivery Technology

  • 6.1. Introduction
  • 6.2. Bispecific Antibody RMT Approach
  • 6.3. Passive Diffusion
  • 6.4. Permeability Increase of BBB
  • 6.5. Trojan Horse Approach

7. Drug Delivery Across Blood Brain Barrier Market, by Application

  • 7.1. Introduction
  • 7.2. Alzheimer's Disease
  • 7.3. Brain Cancer
  • 7.4. Epilepsy
  • 7.5. Hunter's Syndrome
  • 7.6. Multiple Sclerosis
  • 7.7. Parkinson's Disease

8. Americas Drug Delivery Across Blood Brain Barrier Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Drug Delivery Across Blood Brain Barrier Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Drug Delivery Across Blood Brain Barrier Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. 3M Company
  • 2. AbbVie Inc.
  • 3. Angiochem Inc.
  • 4. Bioasis Technologies Inc.
  • 5. Boehringer Ingelheim International GmbH
  • 6. Bristol-Myers Squibb Company
  • 7. Carthera S.A.
  • 8. CNS Pharmaceuticals, Inc.
  • 9. Cordance Medical Inc.
  • 10. F. Hoffmann-La Roche Ltd.
  • 11. ICON PLC
  • 12. JCR Pharmaceuticals Co., Ltd.
  • 13. Nanoform Finland Oyj
  • 14. Ossianix, Inc.
  • 15. Pfizer Inc.

LIST OF FIGURES

  • FIGURE 1. DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET RESEARCH PROCESS
  • FIGURE 2. DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG DELIVERY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG DELIVERY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET DYNAMICS
  • TABLE 7. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG DELIVERY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY BISPECIFIC ANTIBODY RMT APPROACH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY PASSIVE DIFFUSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY PERMEABILITY INCREASE OF BBB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY TROJAN HORSE APPROACH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY BRAIN CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY HUNTER'S SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG DELIVERY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG DELIVERY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG DELIVERY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. CANADA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG DELIVERY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. MEXICO DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG DELIVERY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 29. MEXICO DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. UNITED STATES DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG DELIVERY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 31. UNITED STATES DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. UNITED STATES DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 33. ASIA-PACIFIC DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG DELIVERY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 34. ASIA-PACIFIC DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. ASIA-PACIFIC DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 36. AUSTRALIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG DELIVERY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 37. AUSTRALIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. CHINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG DELIVERY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 39. CHINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. INDIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG DELIVERY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 41. INDIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. INDONESIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG DELIVERY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 43. INDONESIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. JAPAN DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG DELIVERY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 45. JAPAN DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. MALAYSIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG DELIVERY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 47. MALAYSIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. PHILIPPINES DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG DELIVERY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 49. PHILIPPINES DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. SINGAPORE DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG DELIVERY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 51. SINGAPORE DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. SOUTH KOREA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG DELIVERY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 53. SOUTH KOREA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. TAIWAN DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG DELIVERY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 55. TAIWAN DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. THAILAND DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG DELIVERY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 57. THAILAND DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. VIETNAM DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG DELIVERY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 59. VIETNAM DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG DELIVERY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 61. EUROPE, MIDDLE EAST & AFRICA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 63. DENMARK DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG DELIVERY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 64. DENMARK DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. EGYPT DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG DELIVERY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 66. EGYPT DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. FINLAND DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG DELIVERY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 68. FINLAND DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. FRANCE DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG DELIVERY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 70. FRANCE DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. GERMANY DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG DELIVERY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 72. GERMANY DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. ISRAEL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG DELIVERY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 74. ISRAEL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. ITALY DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG DELIVERY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 76. ITALY DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. NETHERLANDS DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG DELIVERY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 78. NETHERLANDS DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. NIGERIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG DELIVERY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 80. NIGERIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. NORWAY DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG DELIVERY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 82. NORWAY DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. POLAND DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG DELIVERY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 84. POLAND DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. QATAR DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG DELIVERY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 86. QATAR DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. RUSSIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG DELIVERY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 88. RUSSIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. SAUDI ARABIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG DELIVERY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 90. SAUDI ARABIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH AFRICA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG DELIVERY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH AFRICA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. SPAIN DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG DELIVERY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 94. SPAIN DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. SWEDEN DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG DELIVERY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 96. SWEDEN DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. SWITZERLAND DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG DELIVERY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 98. SWITZERLAND DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. TURKEY DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG DELIVERY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 100. TURKEY DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED ARAB EMIRATES DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG DELIVERY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED ARAB EMIRATES DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED KINGDOM DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG DELIVERY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED KINGDOM DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 106. DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET, FPNV POSITIONING MATRIX, 2023